胰腺癌新辅助治疗现状及挑战

Current status and challenges of neoadjuvant therapy for pancreatic cancer

胰腺癌是恶性程度极高的实体肿瘤之一,其发病率不断上升,预后极差。近年来,新辅助治疗能够消除肿瘤微转移灶、提高根治性手术切除率、改善病人预后而逐渐成为胰腺癌领域的研究热点之一。然而,胰腺癌新辅助治疗在适应人群的选择、治疗方案的选择、疗效评估及可切除性预测等方面存在较大争议。本文对胰腺癌新辅助治疗的现状及存在的争议进行综述。

Pancreatic cancer is one of the most malignant solid tumors with an increasing incidence and poor prognosis.In recent years,neoadjuvant therapy has gradually become one of the research hotspots in the field of pancreatic cancer,which is aimed at eliminating tumor micrometastases,improving the radical resection rate and improving the prognosis of patients.However,there is a great controversy in the selection of suitable population,treatment options,efficacy evaluation and resectability prediction of neoadjuvant therapy for pancreatic cancer.This article reviews the current status and controversial issues of neoadjuvant therapy for pancreatic cancer,aiming to promote the standardized treatment of pancreatic cancer.